2025年1月8日，Viking ...

Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

圣地亚哥 - Viking Therapeutics, Inc. (NASDAQ: VKTX)过去一年股价上涨了令人印象深刻的114%，该公司已经启动了VK2735的二期临床试验，这是一种旨在治疗肥胖症和相关代谢疾病的口服药物。根据 InvestingPro ...

Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual ...

Viking Therapeutics (VKTX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Annabel Samimy.Stay Ahead of the ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

圣地亚哥—根据最近的SEC文件显示，Viking Therapeutics, Inc. (NASDAQ:VKTX)的首席财务官Zante Greg最近出售了公司大量股票。Greg于2025年1月6日在两笔独立交易中共售出50,309股。这些股票的售价在42.6888美元至43.3194美元之间，总计约215万美元。此次交易发生之际，Viking的股票交易价格高于其 InvestingPro ...

It's been an excellent year for Viking Therapeutics ( VKTX 4.30%), a mid-cap biotech company. Thanks to impressive mid-stage ...

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...

智通财经APP获悉，Viking Therapeutics(VKTX.US)宣布，其试验性药物VK2735在较高剂量下相比早期配方能更有效地减轻患者体重，这为其与诺和诺德(NVO.US ...

Viking Therapeutics ( VKTX -2.05%) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's ...

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.